Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH) – Investment analysts at William Blair lowered their FY2017 earnings estimates for Spring Bank Pharmaceuticals in a research note issued on Wednesday. William Blair analyst Y. Xu now anticipates that the company will post earnings of ($3.35) per share for the year, down from their previous estimate of ($2.53). William Blair also issued estimates for Spring Bank Pharmaceuticals’ Q4 2017 earnings at ($0.86) EPS, Q1 2018 earnings at ($0.90) EPS, Q2 2018 earnings at ($0.90) EPS, Q3 2018 earnings at ($0.91) EPS, Q4 2018 earnings at ($0.91) EPS and FY2018 earnings at ($3.62) EPS.
ILLEGAL ACTIVITY WARNING: This story was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this story on another publication, it was copied illegally and reposted in violation of United States and international copyright and trademark legislation. The legal version of this story can be accessed at https://www.com-unik.info/2017/11/06/william-blair-weighs-in-on-spring-bank-pharmaceuticals-inc-s-fy2017-earnings-sbph.html.
Other analysts have also issued research reports about the stock. Cantor Fitzgerald assumed coverage on shares of Spring Bank Pharmaceuticals in a report on Wednesday, July 19th. They set an “overweight” rating and a $29.00 target price for the company. ValuEngine lowered shares of Spring Bank Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, August 11th. Dawson James reaffirmed a “buy” rating on shares of Spring Bank Pharmaceuticals in a report on Monday, August 7th. Finally, Chardan Capital reaffirmed a “buy” rating on shares of Spring Bank Pharmaceuticals in a report on Sunday, September 17th. One analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the stock. Spring Bank Pharmaceuticals currently has a consensus rating of “Hold” and a consensus price target of $26.33.
Shares of Spring Bank Pharmaceuticals (SBPH) opened at $15.73 on Monday. Spring Bank Pharmaceuticals has a fifty-two week low of $6.31 and a fifty-two week high of $17.94.
Several hedge funds have recently made changes to their positions in SBPH. Private Capital Advisors Inc. grew its holdings in shares of Spring Bank Pharmaceuticals by 50.0% in the 2nd quarter. Private Capital Advisors Inc. now owns 56,250 shares of the company’s stock valued at $762,000 after buying an additional 18,750 shares during the period. Morse Asset Management Inc grew its holdings in shares of Spring Bank Pharmaceuticals by 156.9% in the 2nd quarter. Morse Asset Management Inc now owns 63,700 shares of the company’s stock valued at $862,000 after buying an additional 38,900 shares during the period. C WorldWide Group Holding A S acquired a new position in shares of Spring Bank Pharmaceuticals in the 2nd quarter valued at $340,000. Sphera Funds Management LTD. acquired a new position in shares of Spring Bank Pharmaceuticals in the 2nd quarter valued at $2,370,000. Finally, AXA acquired a new position in shares of Spring Bank Pharmaceuticals in the 2nd quarter valued at $2,894,000. 28.23% of the stock is owned by institutional investors.
Spring Bank Pharmaceuticals Company Profile
Spring Bank Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of a class of therapeutics using its small molecule nucleic acid hybrid (SMNH) chemistry platform. The Company is developing its SMNH product, SB 9200, for the treatment of viral diseases.
What are top analysts saying about Spring Bank Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Spring Bank Pharmaceuticals Inc. and related companies.